Haifa, Israel, October 26th, 2026, FinanceWire

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine.

Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure.

• Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources.
• Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.
• Broader product and clinical-development opportunities: The companies intend to expand commercial offerings, including regenerative aesthetics, and combine scientific resources to strengthen and advance selected clinical programs.
• Aligned ownership: The transaction and contemplated additional share exchange will result in Pluri owning 50% of ZEO at Closing following the completion of the applicable transaction steps. 

Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive strategic agreement (“Partnership Agreement”) to expand the parties U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.

ZEO brings an established U.S. biologics business combining scientific and manufacturing capabilities with the infrastructure needed to reach and support physicians. Its existing biologics portfolio, substantial physician network, established sales channel, dedicated marketing department, and educational programming provide a foundation for introducing additional products and expanding commercial operations.

Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and its Cellav Health and Aesthetics Ltd.’s (“Cellav”) regenerative aesthetics portfolio.

Together, the companies intend to connect these complementary capabilities to broaden product offerings, expand commercial reach, and strengthen selected regenerative-development programs, subject to applicable regulatory requirements.

Expanding Opportunities in Regenerative Aesthetics

The Partnership Agreement also provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. Cellav, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO’s commercial platform.

Advanced Product Development

Pluri brings more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia (CLI), supported by extensive scientific and clinical data and an intellectual property portfolio of over 200 patents. By combining Pluri’s accumulated knowledge and development experience with ZEO’s research, manufacturing, and commercial capabilities, the companies aim to develop and bring to market advanced therapeutic products, supported by scientific evidence and informed by extensive clinical data.

Leadership Perspectives

Ian Bothwell, Chief Executive Officer of ZEO ScientifiX commented: “Pluri brings capabilities that are exceptionally valuable to our business: proprietary cell technology, two decades of scientific and clinical experience, and proven expertise in scalable cell manufacturing. We believe combining these strengths with ZEO’s scientific expertise and commercial infrastructure will allow us to expand our product portfolio, accelerate innovation, and pursue opportunities that neither company could address as effectively on its own. We are excited to partner with Pluri and build a stronger platform for the future of regenerative medicine.”

Yaky Yanay, President and Chief Executive Officer of Pluri commented: “ZEO has built something highly valuable: an established U.S. commercial platform with direct access to physicians, an existing advanced product portfolio, and dedicated sales, marketing, and educational capabilities. For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market. We believe this partnership can accelerate commercialization, expand our reach in the U.S., and support our ambition to build a growing regenerative medicine business.”

Transaction Overview

Under the Partnership Agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how for associated with its regenerative medicine associated assets, while retaining ownership of its underlying technology and intellectual property. In consideration, ZEO will initially issue shares of its common stock representing 50% of its issued and outstanding common stock immediately following Closing. The Partnership Agreement also provides for warrants, corporate governance and protective rights, among other matters, as well as customary representations and warranties, covenants and indemnifications of the parties.

Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements.

Closing of the proposed transaction, which is expected to occur in the fourth quarter of 2026 is subject to satisfaction of a number of conditions, including the negotiation of various ancillary agreements, securing certain approvals and the delivery of valuations, as well as other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.

About Pluri

Pluri is a biotechnology company advancing cell-based solutions for health and longevity. Powered by its proprietary 3D cell expansion platform, Pluri develops and manufactures innovative cell-based products designed to address significant unmet medical needs and support healthier, longer lives. With decades of expertise in cell science, clinical development and scalable manufacturing, Pluri is building a portfolio of regenerative and longevity-focused solutions while leveraging its technology and manufacturing capabilities through strategic partnerships. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

About ZEO ScientifiX

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations. Based at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, ZEO combines scientific and manufacturing expertise with a substantial physician network, dedicated sales and marketing resources, and physician education infrastructure. Through internal development and strategic partnerships, ZEO seeks to expand its product portfolio and advance regenerative medicine. To learn more, visit www.zeoscientifix.com or follow ZEO on LinkedIn, Facebook and Instagram.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. securities laws, including statements regarding transaction completion and timing; licensing, ownership, and accounting consolidation; integration; product development and commercialization; clinical programs, and anticipated strategic and financial benefits.

Actual results could differ materially due to risks including failure to complete the transaction; integration challenges; insufficient funding; unsuccessful development, clinical trials, or commercialization; manufacturing and supply issues; competition; and changes in applicable federal and state regulatory requirements. Prior clinical experience does not assure future success.

Additional risks are described in the companies’ respective SEC filings. Neither company undertakes to update forward-looking statements except as required by law.

Contact

Investor Relations
Pluri Inc.
investor.relations@pluri-biotech.com

MUGGIÒ, Italy, October 24th, 2026, FinanceWire

Tecnover, the Italian manufacturer of professional spray-painting equipment, is celebrating more than four decades of innovation in spray-painting technology. Founded in 1984, the family-run company has grown from a small workshop near Milan into an international supplier of professional equipment, serving customers across construction, metalwork, woodworking, marine and industrial sectors.

From a Small Workshop to a Global Exporter

Tecnover was founded on October 2, 1984, by Francesco Ricotti and Lorenza Cera, who combined their experience in the paint trade with practical knowledge of spray-painting equipment sales and service. At its original headquarters in Sesto San Giovanni, near Milan, the company developed its first airless paint sprayer, establishing the foundation for its product portfolio.

Today, the business is led by the second generation, Stefano and Massimo Ricotti. Based in Muggiò, Italy, Tecnover operates its offices, warehouse, showroom and production facilities from a single location. Its equipment and accessories are distributed to professional customers in markets around the world.

The company continues to build on its Italian manufacturing heritage while developing solutions designed to meet the evolving needs of painting professionals.

Airless Technology at the Core

Airless painting technology forces paint through a precisely sized nozzle at high pressure without using compressed air to atomize the material. This process enables efficient paint application while helping reduce overspray when equipment is used correctly.

Tecnover markets its professional airless paint sprayers under the Testarossa name. The product range includes portable electric models, petrol-engine machines for job sites without convenient access to electricity, gravity-tank configurations and the Marine M12, designed for nautical applications.

The company also supplies essential accessories and replacement components, including hoses, nozzles, filters and spare parts, helping professionals maintain their equipment and support long-term operational performance.

Revolver Introduces a New Approach to Airless Spray Guns

Among Tecnover’s product developments is the Airless Revolver line of professional spray guns and accessories. Its 90-degree magnetic rotation mechanism allows operators to change the spray fan orientation with a single finger, without tools or the need to interrupt their work.

The Revolver range is available in European and American thread configurations. Tecnover also offers the Fan Revolver accessory, which brings the rotating spray-pattern feature to compatible existing spray guns.

These solutions are designed to improve convenience and adaptability during professional painting operations.

Beyond Airless: HVLP and Continuous-Air Systems

In addition to airless equipment, Tecnover offers HVLP (high volume, low pressure) turbine systems for controlled finishing applications. Its product portfolio includes the three-stage Airbass Turbo 800 and the two-stage Turboshort 1000.

The company also manufactures the Short 110 series for continuous-air spray painting, offering an alternative approach to conventional cup-gun systems.

Together, these technologies address a wide range of professional requirements, from construction and metalworking to woodworking, marine projects and industrial finishing.

Made in Italy, Available Worldwide

Tecnover designs and manufactures its machines in Italy, with equipment undergoing testing before shipment. The company provides customer support by telephone on weekdays and through WhatsApp, allowing customers to contact its team for product-related assistance.

Visitors can also explore the company’s Muggiò showroom through an online 3D tour. In addition to its own online store, which offers free shipping throughout Italy, Tecnover products are available through several marketplaces and trade platforms, including Amazon, ArchiExpo, DirectIndustry, Edillo, eBay, Fareke, Alibaba and Subito.

By combining Italian manufacturing, product development and international distribution, Tecnover continues to serve professionals seeking equipment and accessories for a variety of spray-painting applications.

About Tecnover

Tecnover s.n.c. di Ricotti e Cera is an Italian manufacturer of professional spray-painting equipment founded in 1984 and headquartered in Muggiò, Monza and Brianza, Italy. The company designs and produces airless paint sprayers, HVLP turbines and continuous-air systems, along with accessories and spare parts for professional applications in construction, metalwork, woodworking, marine and industrial sectors.

For more information, visit https://tecnover.com/en/.

Contact

TECNOVER Corporate Communications
info@tecnover.com